Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) EBIT (2023 - 2025)

Immunocore Holdings' EBIT history spans 3 years, with the latest figure at -$19.7 million for Q4 2025.

  • For Q4 2025, EBIT fell 1.23% year-over-year to -$19.7 million; the TTM value through Dec 2025 reached -$45.4 million, up 35.63%, while the annual FY2025 figure was -$45.4 million, 35.63% up from the prior year.
  • EBIT for Q4 2025 was -$19.7 million at Immunocore Holdings, down from -$7.2 million in the prior quarter.
  • Across five years, EBIT topped out at -$3.6 million in Q1 2025 and bottomed at -$26.5 million in Q1 2024.
  • The 3-year median for EBIT is -$14.8 million (2023), against an average of -$14.6 million.
  • The largest annual shift saw EBIT crashed 80.25% in 2024 before it soared 86.35% in 2025.
  • A 3-year view of EBIT shows it stood at -$17.1 million in 2023, then fell by 14.07% to -$19.5 million in 2024, then fell by 1.23% to -$19.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's EBIT are -$19.7 million (Q4 2025), -$7.2 million (Q3 2025), and -$14.9 million (Q2 2025).